İlhan HACIBEKİROĞLU, Bülent ERDOĞAN, Hilmi TOZKIR, Ebru TAŞTEKİN, Sernaz UZUNOĞLU, Hakan GÜRKAN, İrfan ÇİÇİN, Esma TÜRKMEN, Hilmi KODAZ, Bora DEMİRKAN

KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

Background: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung can-cer (NSCLC) and small cell lung cancer (SCLC). Extrapul-monary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different.Aims: We investigated the KRAS mutation status in SCLC and EPSCC.Study design: Mutation research.Methods: Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isola-tion was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qia-gen; Hilden, Germany) was used for KRAS analyses. Results: Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were fe-male. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no differ-ence was found for overall survival (p=0.6).Conclusion: In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCLC

PDF

___

Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. [Crossref]
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. [Crossref]
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. N Engl J Med 2010;363:1693-703. [Crossref]
Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794- 801.
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355-67. [Crossref]
Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96. [Crossref]
Wong YN, Jack RH, Mak V, Henrik M, Davies EA. The epide- miology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer 2009;9:209. [Crossref]
Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, San- chez J, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012;13:12153-68. [Crossref]
Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8. [Crossref]
Cicin I, Usta U, Karagol H, Uzunoglu S, Kocak Z. Extrapul- monary small cell carcinoma localized in lymph nodes: is it a different clinical entity? Acta Oncol 2009;48:354-60. [Crossref]
Cicin I, Karagol H, Uzunoglu S, Uygun K, Usta U, Kocak Z, et al. Extrapulmonary small-cell carcinoma compared with small- cell lung carcinoma: a retrospective single-center study. Cancer 2007;110:1068-76. [Crossref]
Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-4. [Crossref]
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adeno- carcinoma. Genome Res 2012;22:2109-19. [Crossref]
Sos ML, Thomas RK. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene 2012;31:4811-4. [Crossref]
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and mela- noma. Cancer Res 2002;62:6997-7000.
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers--a review. Eur J Cancer 2012;48:1299- 311. [Crossref]
Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina-Vila MA, et al. Clin Lung Cancer 2013;14:205-14. [Crossref]
Shepherd FA, Domerg C, Hainaut P, Janne PA, Pignon JP, Grazia- no S, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early- stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013;31:2173-81. [Crossref]
Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Ja- cobse KC, Jiwa NM, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcino- ma. Cell Oncol (Dordr) 2012;35:189-96. [Crossref]
Maitra A, Tascilar M, Hruban RH, Offerhaus GJ, Albores-Saa- vedra J. Small cell carcinoma of the gallbladder: a clinicopatho- logic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol 2001;25:595-601. [Crossref]
Wakuda K, Kenmotsu H, Serizawa M, Koh Y, Isaka M, Taka- hashi S, et al. Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer 2014;84:139-44. [Crossref]
Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy num- ber gains in human lung cancers. Cancer Res 2008;68:6913-21. [Crossref]
Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Al- bayrak D, et al. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol 2015;3:179-84.
Murtaza BN, Bibi A, Rashid MU, Khan YI, Chaudri MS, Sha- koori AR. Spectrum of K ras mutations in Pakistani colorectal cancer patients. Braz J Med Biol Res 2014;47:35-41. [Crossref]